Effect of Statin Treatment on Urinary AQP2 (uAQP2/01)
NCT02523001 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37
Last updated 2015-08-14
Summary
The purpose of this study is to test the hypothesis that the function and/or regulation of urinary aquaporin 2 in hypercholesterolemic humans is affected by standard statin therapy, as compared with diet alone
Conditions
- Hypercholesterolemia
- Diabetes Insipidus
Sponsors & Collaborators
-
University of Bari
lead OTHER
Principal Investigators
-
Piero Portincasa · University of Bari Medical School
Eligibility
- Min Age
- 40 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2014-05-31
- Completion
- 2015-07-31
Countries
- Italy
Study Locations
More Related Trials
-
Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
NCT00663195 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Somatostatin on ADPKD Heart
NCT02119013 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of the Aquaretic Tolvaptan on Nitric Oxide System
NCT02527863 ·Status: COMPLETED ·Phase: PHASE2
-
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
NCT00381134 ·Status: COMPLETED ·Phase: PHASE2
-
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
NCT02040441 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
NCT00309283 ·Status: COMPLETED ·Phase: PHASE3
-
Thyroid Hormones in ADPKD
NCT05646420 ·Status: COMPLETED ·Phase: NA
-
Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium
NCT05188131 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Statin Use on Aldosterone Secretion
NCT02871687 ·Status: COMPLETED ·Phase: PHASE1
-
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
NCT06190158 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Aldosterone in Diabetic Nephropathy
NCT00870402 ·Status: UNKNOWN ·Phase: PHASE4
-
Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin
NCT02811055 ·Status: COMPLETED ·Phase: PHASE2
-
Hemodynamic Effects of Spironolactone in Patients With Heart Failure
NCT00860340 ·Status: COMPLETED ·Phase: NA
-
Aldosterone Antagonism in Diastolic Heart Failure
NCT00108251 ·Status: COMPLETED ·Phase: PHASE4
-
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01336972 ·Status: COMPLETED ·Phase: PHASE2
-
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT05373264 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
NCT02046395 ·Status: COMPLETED ·Phase: PHASE4
-
Aldosterone and Vascular Disease in Diabetes Mellitus
NCT00214825 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
NCT05323487 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of CIN-107 in Adults With Primary Aldosteronism
NCT04605549 ·Status: COMPLETED ·Phase: PHASE2
-
Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure
NCT01973335 ·Status: COMPLETED ·Phase: PHASE4
-
Protocolized Diuretic Strategy in Cardiorenal Failure
NCT01921829 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
NCT01598740 ·Status: COMPLETED ·Phase: PHASE1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
NCT06209359 ·Status: RECRUITING ·Phase: PHASE1
-
Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
NCT01667614 ·Status: COMPLETED ·Phase: PHASE2